Characterization of changes in Serum anti-glycan antibodies in Crohn's disease - a longitudinal analysis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Rieder, Florian ^a,b   Lopez, Rocio ^b   Franke, Andre ^c   Wolf, Alexandra ^a   Schleder, Stephan ^a   Dirmeier, Andrea ^a   Schirbel, Anja ^b   Rosenstiel, Philip ^c   Dotan, Nir ^d   Schreiber, Stefan ^c   Rogler, Gerhard ^e   Klebl, Frank ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF KIEL   (Germany)

^d Glycominds Ltd   (Israel)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHITIN; CHITOBIOSE; GLYCAN; LAMINARAN; MANNOSE; PROTEIN ANTIBODY; SACCHAROMYCES CEREVISIAE PROTEIN; ANTIBODY; DISACCHARIDE; MANNAN; MANNOBIOSE; POLYSACCHARIDE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HUMAN; IMMUNOREACTIVITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PHENOTYPIC VARIATION; SENSITIVITY AND SPECIFICITY; SEROLOGY; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; IMMUNOLOGY;

SACCHAROMYCES CEREVISIAE;

ADOLESCENT; ADULT; ANTIBODIES; CHITIN; CROHN DISEASE; DISACCHARIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MANNANS; POLYSACCHARIDES; YOUNG ADULT;

EID: 79955827789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018172     Document Type: Article

References (29)

1. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, et al. (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 55 (Suppl 1): i1-15.
2. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, et al. (2001) Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49: 777-782.
3. Farmer RG, Whelan G, Fazio VW, (1985) Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88: 1818-1825.
4. Andres PG, Friedman LS, (1999) Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 28: 255-281.
5. Devlin SM, Dubinsky MC, (2008) Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis 14: 125-128.
6. Targan SR, (1999) The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis 5: 61-63.
7. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, et al. (2007) New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56: 1394-1403.
8. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, et al. (2006) Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131: 366-378.
9. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, et al. (2008) New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 103: 665-681.
10. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, et al. (2010) Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 16: 1367-1375.
11. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, et al. (2010) Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis 16: 263-274.
12. Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, et al. (2008) Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 14: 645-651.
13. Seow CH, Stempak JM, Xu W, Lan H, Griffiths AM, et al. (2009) Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 104: 1426-1434.
14. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, et al. (2004) Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126: 414-424.
15. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, et al. (2008) Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children. Clin Gastroenterol Hepatol 10: 1105-1111.
16. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, et al. (1998) Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115: 822-829.
17. Oshitani N, Hato F, Matsumoto T, Jinno Y, Sawa Y, et al. (2000) Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease. J Gastroenterol Hepatol 15: 1400-1403.
18. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, et al. (2004) Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 99: 2376-2384.
19. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, et al. (2002) Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123: 689-699.
20. Teml A, Kratzer V, Schneider B, Lochs H, Norman GL, et al. (2003) Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 98: 2226-2231.
21. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, et al. (2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128: 2020-2028.
22. Eser A, Papay P, Miehsler W, Dejaco C, Gangl A, et al. (2009) Impact of Intestinal Resection On and Prognostic Value of Anti-Saccharomyces Cerevisiae Serology in Patients with Crohn's Disease During Long-Term Follow-Up Gastroenterology 136: A-188.
23. Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, et al. (2004) Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2: 139-146.
24. Spivak J, Landers CJ, Vasiliauskas EA, Abreu MT, Dubinsky MC, et al. (2006) Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis 12: 1122-1130.
25. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, et al. (2008) European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohn's and Colitis 2: 1-23.
26. Teuber M, Koch A, Manaster C, Wachter S, Hampe J, et al. (2005) Improving quality control and workflow management in high-throughput single-nucleotide polymorphism genotyping environments Journal of the Association for Laboratory Automation 2005: 43-47.
27. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, et al. (2005) Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54: 1232-1236.
28. Dotan N, Altstock RT, Schwarz M, Dukler A, (2006) Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus 15: 442-450.
29. Bartunkova J, Kolarova I, Sediva A, Holzelova E, (2002) Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin Immunol 102: 162-168.